Fluconazole-Darnitsa
Release forms:
- Capsules
- Solution for infusion
In adults, for the treatment of:
– cryptococcal meningitis;
– coccidioidosis;
– invasive candidiasis;
– mucosal candidiases including candidiasis of the oropharynx and oesophagus, candiduria, chronic candidiasis of the skin and mucosa;
– chronic atrophic candidiasis (candidiasis caused by the use of dentures) if local therapy is ineffective.
In adults, for the prevention of:
– relapse of cryptococcal meningitis in patients with a high risk of its development;
– relapse of candidiasis of the oropharynx and oesophagus in patients with HIV with a high risk of its development;
– prevention of candidal infections in patients with prolonged neutropenia (e.g. in patients with blood malignancies receiving chemotherapy, or in patients with haematopoietic stem cell transplantation).
Characteristics of the productу:
Release formInfusion solution
ChildrenAllowed
PregnantContraindicated
NursingContraindicated
Release categoryPrescription medication
Temperature storage conditionsNot higher than 25 °С
- Qualitative and quantitative composition:
- Pharmaceutical form
- Pharmacotherapeutic group
- Pharmacological properties.
- Clinical particulars
- Therapeutic indications.
- Contraindications.
- Interaction with other medicinal products and other forms of interaction
- Special warnings and precautions for use.
- Posology and method of administration.
- Overdose.
- Undesirable effects.
- Shelf life
- Special precautions for storage
- Incompatibilities.
- Nature and contents of container
- Category of release
- Manufacturer
- The manufacturer's location and address of the place of business
- Date of the last revision